Display options
Cite
van Veldhoven K, Polidoro S, Baglietto L, et al. Epigenome-wide association study reveals decreased average methylation levels years before breast cancer diagnosis. Clin Epigenetics. 2015;7:67doi: 10.1186/s13148-015-0104-2.
van Veldhoven, K., Polidoro, S., Baglietto, L., Severi, G., Sacerdote, C., Panico, S., Mattiello, A., Palli, D., Masala, G., Krogh, V., Agnoli, C., Tumino, R., Frasca, G., Flower, K., Curry, E., Orr, N., Tomczyk, K., Jones, M. E., Ashworth, A., Swerdlow, A., Chadeau-Hyam, M., Lund, E., Garcia-Closas, M., Sandanger, T. M., Flanagan, J. M., & Vineis, P. (2015). Epigenome-wide association study reveals decreased average methylation levels years before breast cancer diagnosis. Clinical epigenetics, 767. https://doi.org/10.1186/s13148-015-0104-2
van Veldhoven, Karin, et al. "Epigenome-wide association study reveals decreased average methylation levels years before breast cancer diagnosis." Clinical epigenetics vol. 7 (2015): 67. doi: https://doi.org/10.1186/s13148-015-0104-2
van Veldhoven K, Polidoro S, Baglietto L, Severi G, Sacerdote C, Panico S, Mattiello A, Palli D, Masala G, Krogh V, Agnoli C, Tumino R, Frasca G, Flower K, Curry E, Orr N, Tomczyk K, Jones ME, Ashworth A, Swerdlow A, Chadeau-Hyam M, Lund E, Garcia-Closas M, Sandanger TM, Flanagan JM, Vineis P. Epigenome-wide association study reveals decreased average methylation levels years before breast cancer diagnosis. Clin Epigenetics. 2015 Aug 04;7:67. doi: 10.1186/s13148-015-0104-2. eCollection 2015. PMID: 26244061; PMCID: PMC4524428.
Copy Download .nbib Format: NLM
Share it on

Clin Epigenetics. 2015 Aug 04;7:67. doi: 10.1186/s13148-015-0104-2. eCollection 2015.

Epigenome-wide association study reveals decreased average methylation levels years before breast cancer diagnosis.

Clinical epigenetics

Karin van Veldhoven, Silvia Polidoro, Laura Baglietto, Gianluca Severi, Carlotta Sacerdote, Salvatore Panico, Amalia Mattiello, Domenico Palli, Giovanna Masala, Vittorio Krogh, Claudia Agnoli, Rosario Tumino, Graziella Frasca, Kirsty Flower, Ed Curry, Nicholas Orr, Katarzyna Tomczyk, Michael E Jones, Alan Ashworth, Anthony Swerdlow, Marc Chadeau-Hyam, Eiliv Lund, Montserrat Garcia-Closas, Torkjel M Sandanger, James M Flanagan, Paolo Vineis

Affiliations

  1. MRC-PHE Centre for Environment and Health, Imperial College London, London, W2 1PG UK.
  2. HuGeF Foundation, 52, Via Nizza, Torino, 10126 Italy.
  3. Departimento di Medicina Clinica e Chirurgia, Federico II University, Naples, Italy.
  4. Molecular and Nutritional Epidemiology Unit, Cancer Research and Prevention Institute-ISPO, Florence, Italy.
  5. Epidemiology and Prevention Unit Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  6. Cancer Registry ASP, Ragusa, Italy.
  7. Epigenetics Unit, Division of Cancer, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, 4th Floor IRDB, Hammersmith Campus, Du Cane Road, London, W12 0NN UK.
  8. Division of Breast Cancer Research, The Institute of Cancer Research, London, UK.
  9. Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
  10. Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK.
  11. Department of Community Medicine, UiT-the Arctic University of Norway, Tromsø, Norway.

PMID: 26244061 PMCID: PMC4524428 DOI: 10.1186/s13148-015-0104-2

Abstract

BACKGROUND: Interest in the potential of DNA methylation in peripheral blood as a biomarker of cancer risk is increasing. We aimed to assess whether epigenome-wide DNA methylation measured in peripheral blood samples obtained before onset of the disease is associated with increased risk of breast cancer. We report on three independent prospective nested case-control studies from the European Prospective Investigation into Cancer and Nutrition (EPIC-Italy; n = 162 matched case-control pairs), the Norwegian Women and Cancer study (NOWAC; n = 168 matched pairs), and the Breakthrough Generations Study (BGS; n = 548 matched pairs). We used the Illumina 450k array to measure methylation in the EPIC and NOWAC cohorts. Whole-genome bisulphite sequencing (WGBS) was performed on the BGS cohort using pooled DNA samples, combined to reach 50× coverage across ~16 million CpG sites in the genome including 450k array CpG sites. Mean β values over all probes were calculated as a measurement for epigenome-wide methylation.

RESULTS: In EPIC, we found that high epigenome-wide methylation was associated with lower risk of breast cancer (odds ratio (OR) per 1 SD = 0.61, 95 % confidence interval (CI) 0.47-0.80; -0.2 % average difference in epigenome-wide methylation for cases and controls). Specifically, this was observed in gene bodies (OR = 0.51, 95 % CI 0.38-0.69) but not in gene promoters (OR = 0.92, 95 % CI 0.64-1.32). The association was not replicated in NOWAC (OR = 1.03 95 % CI 0.81-1.30). The reasons for heterogeneity across studies are unclear. However, data from the BGS cohort was consistent with epigenome-wide hypomethylation in breast cancer cases across the overlapping 450k probe sites (difference in average epigenome-wide methylation in case and control DNA pools = -0.2 %).

CONCLUSIONS: We conclude that epigenome-wide hypomethylation of DNA from pre-diagnostic blood samples may be predictive of breast cancer risk and may thus be useful as a clinical biomarker.

Keywords: Biomarker; Breast cancer; EWAS; Methylation; Peripheral blood; Risk

References

  1. Curr Genomics. 2012 Jun;13(4):308-13 - PubMed
  2. Nat Genet. 2011 Jun 26;43(8):768-75 - PubMed
  3. Br J Haematol. 2008 Jun;141(6):862-71 - PubMed
  4. J Nutr. 2006 Nov;136(11):2748-53 - PubMed
  5. Hum Mol Genet. 2013 Mar 1;22(5):843-51 - PubMed
  6. Cancer Prev Res (Phila). 2012 Dec;5(12):1345-57 - PubMed
  7. Birth Defects Res C Embryo Today. 2009 Dec;87(4):335-50 - PubMed
  8. Cancer Prev Res (Phila). 2011 Jan;4(1):23-33 - PubMed
  9. Nat Rev Genet. 2011 Jul 12;12(8):529-41 - PubMed
  10. Carcinogenesis. 2014 Feb;35(2):333-8 - PubMed
  11. Bioinformatics. 2011 Jun 1;27(11):1571-2 - PubMed
  12. Epigenomics. 2011 Dec;3(6):771-84 - PubMed
  13. Br J Cancer. 2007 Jul 16;97(2):267-74 - PubMed
  14. Br J Cancer. 2011 Sep 27;105(7):911-7 - PubMed
  15. J Pathol. 2005 Jan;205(2):172-80 - PubMed
  16. Nucleic Acids Res. 1983 Oct 11;11(19):6883-94 - PubMed
  17. Curr Protoc Mol Biol. 2012 Jul;Chapter 21:Unit21.23 - PubMed
  18. Tumori. 2003 Nov-Dec;89(6):586-93 - PubMed
  19. Epigenetics. 2011 Jun;6(6):692-702 - PubMed
  20. PLoS One. 2012;7(10):e46705 - PubMed
  21. Anticancer Res. 2010 Jul;30(7):2489-96 - PubMed
  22. Am J Clin Nutr. 2006 Apr;83(4):895-904 - PubMed
  23. Cancer Res. 2012 May 1;72 (9):2304-13 - PubMed
  24. J Epidemiol. 2012;22(5):384-94 - PubMed
  25. Cancer Epidemiol Biomarkers Prev. 2008 Jun;17(6):1374-9 - PubMed
  26. Cancer Causes Control. 2003 Dec;14(10):1001-8 - PubMed
  27. Carcinogenesis. 2009 Nov;30(11):1889-97 - PubMed
  28. Nature. 1983 Jan 6;301(5895):89-92 - PubMed
  29. Biostatistics. 2007 Jan;8(1):118-27 - PubMed
  30. Environ Health Perspect. 2011 Nov;119(11):1528-33 - PubMed
  31. J Natl Cancer Inst. 2013 May 15;105(10 ):694-700 - PubMed
  32. Genomics. 2011 Oct;98(4):288-95 - PubMed
  33. J Mol Biol. 1987 Jul 20;196(2):261-82 - PubMed
  34. PLoS One. 2012;7(7):e41361 - PubMed
  35. Bioinformatics. 2014 May 15;30(10):1431-9 - PubMed
  36. Bioinformatics. 2013 Jan 15;29(2):189-96 - PubMed
  37. Genome Med. 2014 Jun 27;6(6):47 - PubMed
  38. Breast Cancer Res Treat. 2011 Aug;129(1):69-77 - PubMed
  39. BMC Genomics. 2010 Feb 25;11:137 - PubMed
  40. BMC Bioinformatics. 2012 May 08;13:86 - PubMed
  41. Nat Genet. 2009 Feb;41(2):178-86 - PubMed
  42. Biochem Biophys Res Commun. 1983 Feb 28;111(1):47-54 - PubMed
  43. Breast Cancer Res Treat. 2014 Dec;148(3):665-73 - PubMed
  44. Bioinformatics. 2001 Jun;17(6):520-5 - PubMed
  45. Epigenomics. 2009 Dec;1(2):239-59 - PubMed
  46. BMC Bioinformatics. 2010 Sep 27;11:485 - PubMed
  47. PLoS Genet. 2010 Jul 29;6(7):e1001043 - PubMed
  48. Cancer Biol Ther. 2005 Apr;4(4):440-8 - PubMed

Publication Types

Grant support